These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 2904990)
21. Somatodendritic 5-hydroxytryptamine1A (5-HT1A) autoreceptor function in major depression as assessed using the shift in electroencephalographic frequency spectrum with buspirone. McAllister-Williams RH; Alhaj HA; Massey A; Pankiv J; Reckermann U Psychol Med; 2014 Mar; 44(4):767-77. PubMed ID: 23809646 [TBL] [Abstract][Full Text] [Related]
22. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors. Peng WH; Wu CR; Chen CS; Chen CF; Leu ZC; Hsieh MT Life Sci; 2004 Oct; 75(20):2451-62. PubMed ID: 15350820 [TBL] [Abstract][Full Text] [Related]
23. Dose-dependent response of central dopaminergic systems to buspirone in mice. Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Gursale SC; Balsara JJ Indian J Exp Biol; 2008 Oct; 46(10):704-14. PubMed ID: 19024168 [TBL] [Abstract][Full Text] [Related]
24. Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover. Ballarín M; Carceller A; Guitart X Br J Pharmacol; 1994 Oct; 113(2):425-30. PubMed ID: 7530571 [TBL] [Abstract][Full Text] [Related]
25. The involvement of 5-hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone. Fletcher PJ; Davies M Br J Pharmacol; 1990 Mar; 99(3):519-25. PubMed ID: 2139586 [TBL] [Abstract][Full Text] [Related]
26. Interaction of morphine and 5-hydroxytryptamine in the raphe-hippocampus system. Andreas K; Dude C; Dude G Pol J Pharmacol Pharm; 1979; 31(5):517-21. PubMed ID: 547279 [TBL] [Abstract][Full Text] [Related]
27. Dorsal raphe nucleus lesions have no effect on neuroleptic-induced catalepsy and on the anticataleptic activity of buspirone. Pires JG; Silva SR; Futuro-Neto HA Braz J Med Biol Res; 1991; 24(6):615-7. PubMed ID: 1823280 [TBL] [Abstract][Full Text] [Related]
28. Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Costall B; Jones BJ; Kelly ME; Naylor RJ; Onaivi ES; Tyers MB Pharmacol Biochem Behav; 1990 May; 36(1):97-104. PubMed ID: 2140900 [TBL] [Abstract][Full Text] [Related]
30. Effects of buspirone on the immediate positive and delayed negative properties of intravenous cocaine as measured in the conditioned place preference test. Ettenberg A; Bernardi RE Pharmacol Biochem Behav; 2007 May; 87(1):171-8. PubMed ID: 17524462 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. Kääriäinen TM; Lehtonen M; Forsberg MM; Savolainen J; Käenmäki M; Männistö PT Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):50-8. PubMed ID: 17971064 [TBL] [Abstract][Full Text] [Related]
32. Sustained 5-hydroxytryptamine release-inhibitory and anxiolytic-like action of the partial 5-HT1A receptor agonist, buspirone, after prolonged chronic administration. Söderpalm B; Lundin B; Hjorth S Eur J Pharmacol; 1993 Aug; 239(1-3):69-73. PubMed ID: 7901030 [TBL] [Abstract][Full Text] [Related]
33. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. Millan MJ; Lejeune F; Gobert A; Brocco M; Auclair A; Bosc C; Rivet JM; Lacoste JM; Cordi A; Dekeyne A J Pharmacol Exp Ther; 2000 Dec; 295(3):1206-22. PubMed ID: 11082458 [TBL] [Abstract][Full Text] [Related]
34. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550 [TBL] [Abstract][Full Text] [Related]
35. 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. Wong H; Dockens RC; Pajor L; Yeola S; Grace JE; Stark AD; Taub RA; Yocca FD; Zaczek RC; Li YW Drug Metab Dispos; 2007 Aug; 35(8):1387-92. PubMed ID: 17494642 [TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics. I. Antipunishment effects in the pigeon. Kleven MS; Koek W J Pharmacol Exp Ther; 1996 Feb; 276(2):388-97. PubMed ID: 8632301 [TBL] [Abstract][Full Text] [Related]
37. Anxiolytic-like effect of way-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience. Canto-de-Souza A; Luiz Nunes-de-Souza R; Rodgers RJ Brain Res; 2002 Feb; 928(1-2):50-9. PubMed ID: 11844471 [TBL] [Abstract][Full Text] [Related]
38. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress. Yamaguchi T; Tsujimatsu A; Kumamoto H; Izumi T; Ohmura Y; Yoshida T; Yoshioka M J Ethnopharmacol; 2012 Sep; 143(2):533-9. PubMed ID: 22819689 [TBL] [Abstract][Full Text] [Related]
39. Profile of action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset. Costall B; Domeney AM; Farre AJ; Kelly ME; Martinez L; Naylor RJ J Pharmacol Exp Ther; 1992 Jul; 262(1):90-8. PubMed ID: 1352556 [TBL] [Abstract][Full Text] [Related]
40. 5-HT1A receptors mediate the effect of the bulbospinal serotonin system on spinal dorsal horn nociceptive neurons. Zemlan FP; Murphy AZ; Behbehani MM Pharmacology; 1994 Jan; 48(1):1-10. PubMed ID: 8309982 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]